Navigation Links
HUYA Bioscience International Licenses Clinical Stage Anti-Arrhythmic Compound from the Shanghai Institute of Materia Medica
Date:10/1/2007

SAN DIEGO and SHANGHAI, China, Oct. 2 /PRNewswire/ -- HUYA Bioscience International (HUYA), a rapidly expanding biopharmaceutical company focused on the development of key disease-fighting drugs sourced from China, announced today that it has licensed a novel clinical stage anti-arrhythmic compound from the prestigious Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences.

The compound, HBI-3000 or sulcardine, exhibits a unique profile of myocardial ion channel regulation, compared to approved US and European anti- arrhythmic therapeutics. HBI-3000 has met significant Phase I safety milestones in three completed studies under a SIMM-sponsored Chinese IND. Gary T. Elliott, Pharm.D., Ph.D., Executive Vice President of Product Development at HUYA, commented that "the compound displays an ion channel selectivity profile that may contribute to effective treatment of both ventricular and atrial arrhythmias, while decreasing the risk of sudden death (Torsade de Pointes) associated with some anti-arrhythmics currently on the market."

Mireille Gingras, Ph.D., CEO of HUYA said, "There is a large unmet medical need for safer and more effective treatments for atrial and ventricular arrhythmia. We believe that HBI-3000 has the potential to fill this need, based on its unique properties and significant performance to date. By 2015, the global anti-arrhythmic market is expected to be $3.5 billion, and we feel we are on target to provide an innovative product."

Additional information is available at http://www.huyabio.com.

ABOUT HUYA

HUYA Bioscience International, LLC, with offices in San Diego and Shanghai, capitalizes on the explosive growth of the biotechnology and pharmaceutical industries in China. HUYA identifies and licenses promising Chinese pharmaceuticals for development and commercialization in Western markets. Using its management team and advisors, HUYA lowers the
'/>"/>

SOURCE HUYA Bioscience International, LLC
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Perscitus Biosciences secures $250K Commerce loan
2. Wisconsin biosciences rise to the challenge
3. Quintessence Biosciences advances cancer drug
4. Bioscience clusters: Too many or room for more?
5. Quintessence Biosciences names new president
6. Caden Biosciences may signal critical mass
7. Wisconsin start up Primorigen Biosciences corrals out-of-state investment
8. WARF signs licensing pact with BD Biosciences
9. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
10. Bioscience beats beer
11. State awards QRG Biosciences development grant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... PARK, Calif. , July 23, 2014  Sofinnova ... investment firm, today announced the closing of Sofinnova Venture ... million and in excess of the initial fund target ... helping entrepreneurs build successful biotechnology companies. Consistent with recent ... with promising later stage clinical programs, along with select ...
(Date:7/23/2014)... -- China Cord Blood Corporation (NYSE: CO ) ("CCBC" ... cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem ... company catering to the mother and child segment, today announced that ... PRC, Singapore , Hong Kong ... the Philippines and Malaysia ...
(Date:7/23/2014)... 2014 With the ability to record continuously ... more than 15 minutes, Fastec Imaging has brought the same ... speed imaging. “Finally, a high speed camera that can be ... our everyday lives.” proclaims Matt Kearney, VP of Sales for ... to demystify and simplify the traditionally complicated workflow of a ...
(Date:7/23/2014)... OncLive® is pleased to announce ... its Strategic Alliance Partnership program. , By ... Lineberger will have the opportunity to work with ... cutting-edge research initiatives, community-directed cancer prevention programs, and ... with OncLive to educate their peers by providing ...
Breaking Biology Technology:Sofinnova Raises $500 Million Biotech Venture Fund 2China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 2China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 3China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 4Fastec Imaging Introduces the First High Speed Camcorder 2Fastec Imaging Introduces the First High Speed Camcorder 3OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 2OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 3
... Target Underlying Defect in Cystic Fibrosis; CFTR ... ... BioMarin,Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that it ... covering compounds demonstrated to improve cystic,fibrosis transmembrane conductance regulator (CFTR) ...
... -. Actavis Group, the,international generic pharmaceuticals company, ... the U.S. Food & Drug Administration to ... will begin,immediately. Fentanyl Transdermal System is ... in 25, 50, 75 and 100 mcg/hour ...
... HUNTSVILLE, Ala., Aug. 22 DNA2.0,Inc. ... synthetic genes, and,Operon Biotechnologies (http://www.operon.com ), ... formation of a partnership to utilize their,synergistic ... Operon,s oligonucleotide production platform with DNA2.0,s,gene synthesis ...
Cached Biology Technology:BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco 2BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco 3BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco 4Actavis Receives Approval of Fentanyl Transdermal System in the U.S. 2Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership 2
(Date:7/23/2014)... are crucial for providing essential fatty acids and ... feeding. There has been concern that soybean-based emulsions ... due to its composition. Combination lipid emulsions based ... have been developed to address this concern. , ... that concern may be unwarranted, according to a ...
(Date:7/22/2014)... of both still images and video of artistic ... Forty-four still images were chosen from more than ... and alumni representing more than 25 different University ... 50 submissions. , Zach Donnell, a graduate student ... organizers, noted that the exhibit highlights the interplay ...
(Date:7/22/2014)... Aware, Inc. (NASDAQ: AWRE ), a leading supplier ... its second quarter ended June 30, 2014. Revenue ... increase of 53% compared to $4.4 million in the same ... the second quarter of 2014 was $1.4 million compared to ... in revenue and operating income was driven by higher sales ...
Breaking Biology News(10 mins):Art of Science 2014 2Aware, Inc. Reports Second Quarter 2014 Financial Results 2Aware, Inc. Reports Second Quarter 2014 Financial Results 3Aware, Inc. Reports Second Quarter 2014 Financial Results 4Aware, Inc. Reports Second Quarter 2014 Financial Results 5Aware, Inc. Reports Second Quarter 2014 Financial Results 6Aware, Inc. Reports Second Quarter 2014 Financial Results 7
... years ago Mark Kay, MD, PhD, published the first ... RNA interference was an effective gene-therapy technique in mice. ... flurry amongst both academic and industry research groups. , ... way, Kay's initial excitement is proving to be on ...
... phones excite the brain cortex adjacent to it, ... other neurological conditions. This finding is published in ... & Sons. The article is also available online ... million people in the world use cell phones ...
... as Ritalin to quell symptoms of attention deficit hyperactivity ... drugs work in the brain. , But new work ... clear up some of the mystery. Writing in the ... primarily target the prefrontal cortex (PFC), a region of ...
Cached Biology News:For Stanford scientists, RNAi gene therapy takes two steps forward, one step back 2Cell phone emissions excite the brain cortex 2Study reveals how ADHD drugs work in brain 2Study reveals how ADHD drugs work in brain 3
... Ligands\n\nReceptor-related research has long been enabled by ... selected to keep pace with new discoveries. ... and services for receptor research and drug ... you do not find exactly what you ...
... pending) was developed using a protein engineering approach ... binding pocket of wild-type DNase I. These changes ... DNA. The result is a versatile enzyme that ... an ability to maintain at least 50% of ...
Rabbit polyclonal to hnRNP-U...
... formation of a phosphodiester bonds between adjacent ... DNA molecules or between oligonucleotides which are ... 45 - 65?. Tfi DNA Ligase is ... than conventional DNA ligases, Thus, Tfi DNA ...
Biology Products: